NEW YORK (GenomeWeb News) – Xceleron announced today that it will collaborate with JCL Bioassay in offering drug developers access to their respective technologies for drug screening and development applications.
Xceleron said that the partnership will offer clinical design expertise and appropriate analytical platforms for early clinical investigation. It added that between the firms they have developed more than 100 analytical methods for Phase 0 and Phase 1 investigations.
Germantown, Md.-based Xceleron provides bioanalytical services based on accelerator mass spectrometry technology. Hoffman Estates, Ill.-based JCL Bioassay USA, which is part of Japanese CRO JCL Bioassay, provides bioassay services using LC-MS/MS and other methodologies.
The alliance covers Asia, Europe, and North America. Further terms of the agreement were not disclosed.